What is CJC-1295？

Description

As a synthetic GHRH (growth hormone-releasing hormone), CJC-1295 is an analog made up of 30 amino acids. It is a growth hormone secretagogue (GHS) that was developed by ConjuChem Biotechnologies.

Special property

Compared to the native protein sequence, CJC-1295 has four amino acid substitutions which improve protease resistance, and an additional lysine residue at the C-terminus that incorporates a maleimidopropionic acid group. This maleimidopropionic acid sometimes called the drug affinity complex (DAC), forms stable covalent linkages with free thiol groups on the surface of plasma proteins such as serum albumin[1]. These CJC‐1295‐protein conjugates have a much greater half‐life compared to the unconjugated peptide and are capable of stimulating GH production for more than six days in humans after a single administration[2].

Uses and benefits

The extended plasma half-life of CJC-1295 compared to other peptide drugs with short half-lives makes it an attractive target for drug screening. However, due to its high molecular weight and similarity to abundant plasma proteins, coupled CJC-1295 is not easily detected by mass spectrum-based peptide screening. It is highly effective with regards to the increase of growth hormone secretion and IGF-1 without negatively affecting the pulsatility of GH secretion. Interestingly, it promotes slow-wave deep sleep, which is responsible for the highest levels of muscle growth memory retention, and recovery[1]. In general, it is recognized that it has many health benefits, including:

Increased growth hormone secretion and IGF-1 Levels with no increase in prolactin;

Increased Body Weight and Length through increased protein synthesis;

Increased Muscle Growth;

Increased Bone Density;

Improved Immune Function;

Improved Cognition and Memory;

Increased Collagen Production;

Increased Fat Loss;

Increased Cellular Repair and Regeneration.

Toxicity

CJC-1295 was well tolerated in all animals with no evidence of either local or systemic toxicity. Animals receiving a daily dose of CJC-1295 maintained normal total body weight and N-A measurements through the end of the 5-week treatment period[3]. Animals treated every 48 and 72 h had significantly greater total body weight and N-A compared with GHRHKO/pbo animals, but these measurements remained significantly smaller compared with both HTZ and CJC/24 h mice.

References

[1] Alba M, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology-Endocrinology and Metabolism, 2006; 291: E1290-E1294.

[2] Timms M, et al. A method for confirming CJC-1295 abuse in equine plasma samples by LC-MS/MS. Drug Testing and Analysis, 2019; 11: 1248-1257.

[3] Teichman S, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of Clinical Endocrinology & Metabolism, 2005; 91: 799–805.

You may like